Literature DB >> 10536130

Biliary tract cancers.

P C de Groen1, G J Gores, N F LaRusso, L L Gunderson, D M Nagorney.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10536130     DOI： 10.1056/NEJM199910283411807

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  296 in total

1.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors:  Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

Review 3.  Photodynamic therapy in the biliary tract.

Authors:  M Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-04

4.  Hepatic and extrahepatic malignancies and primary sclerosing cholangitis.

Authors:  E Schrumpf; K M Boberg
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

5.  Targeting PDGFR-β in Cholangiocarcinoma.

Authors:  Christian D Fingas; Joachim C Mertens; Nataliya Razumilava; Steven F Bronk; Alphonse E Sirica; Gregory J Gores
Journal:  Liver Int       Date:  2011-12-02       Impact factor: 5.828

6.  Apoptotic activity of caged xanthones from Garcinia hanburyi in cholangiocarcinoma cell lines.

Authors:  Chariya Hahnvajanawong; Wongwarut Boonyanugomol; Tapanawan Nasomyon; Watcharin Loilome; Nisana Namwat; Natthinee Anantachoke; Wichittra Tassaneeyakul; Banchob Sripa; Wises Namwat; Vichai Reutrakul
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

7.  Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM.

Authors:  Zhi-Hua Liu; Yan-Ping He; Yukun Zhou; Peng Zhang; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2010-01-29       Impact factor: 2.316

8.  Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Authors:  Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-28       Impact factor: 3.333

9.  Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers.

Authors:  Shih-Chang Chuang; King-Teh Lee; Kun-Bow Tsai; Pai-Ching Sheen; Eishi Nagai; Kazuhiro Mizumoto; Masao Tanaka
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

10.  Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe.

Authors:  Jiro Okami; Keizo Dono; Masato Sakon; Masanori Tsujie; Nobuyasu Hayashi; Yoshiyuki Fujiwara; Hiroaki Nagano; Koji Umeshita; Shoji Nakamori; Morito Monden
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.